ABOUT
RONA THERAPEUTICS
Rona Therapeutics is a world-leading nucleic acid therapeutics company dedicated to addressing metabolic and degenerative diseases.
Since its inception in 2021, Rona Therapeutics has advanced several potential best-in-class siRNA therapeutics in the clinic. With longer duration, deep knockdown and improved tolerability, Rona Therapeutics' metabolic assets have demonstrated a differentiated profile to address unmet needs in cardiovascular diseases, MASH and obesity.
Rona Therapeutics has built a proprietary extrahepatic delivery platform in obesity and neurodegenerative diseases to fully exploit nucleic acid delivery potential beyond the liver. With robust knockdown potency and long-term duration (Q9M or longer), multiple assets are progressing into IND-enabling stage to treat complex diseases that cannot be treated with conventional modalities.
The Company has raised around $200M USD from global leading long-only funds and strategic partners.
MANAGEMENT TEAM
Stella (Yibin) Shi
Chief Executive Officer
Alex M. DePaoli, M.D.
Chief Medical Officer and Executive Vice President of Translational Research
Jinyu Huang, Ph.D.
Senior Vice President of Chemistry
Ling Pan, Ph.D.
Executive Vice President of Discovery & Research
Joshua (Jianhua) Yu, Ph.D.
Vice President of CMC
Jasper (Zhuocheng) Tu
Vice President of Finance and Corporate Development
PARTNERS
PARTNERS
EVENTS
Scroll to View
2021
August 2021
Rona Therapeutics company inception
2022
April 2022
Successfully closed Series A financing round of $33 Million participated by long-term institutional investors such as CMBI and LAV.
2023
February 2023
Co-development collaboration with EnnovaBio to jointly discover and develop a novel siRNA program liver diseases associated with metabolism utilizing Rona proprietary siRNA platform
May 2023
Co-development collaboration with Keymed to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases)
August 14, 2023
Entering clinical stage with first subject dose of RN0191 (an innovative PCSK9 siRNA therapy) in Australian Ph1 study
December 29, 2023
RN0191’s IND approval in China National Medical Products Administration (NMPA)
2024
January 2024
First subject dos of RN0191 for China Ph1 study in Peking University Third Hospital
July 2024
Successfully secured a $35 million Series A+ funding round, to propel the clinical advancement of our groundbreaking metabolic siRNA pipeline and the development of next-generation RNA platforms
September 02, 2024
2nd Pipeline asset RN0361 (an innovative APOC3 siRNA therapy) accomplished FIH dosing in Australia
Nov. 2024
Rona Therapeutics was named one of the Top 100 Front-Runners in the China Biopharmaceutical Industry.
2025
January 2025
Dr. Alex DePaoli joined Rona Therapeutics as Chief Medical Officer.
March 2025
Successfully secured $25 million Pre-B funding to accelerate global clinical pipeline deployment and innovative drug development
March 2025
RN0361 obtained FDA IND approval for the Phase 2 study.
April 2025
RN1871 received NMPA IND approval for the Phase 1 study.
July 2025
Rona Therapeutics was named one of the Best Innovative Companies in the 9th Healthcare Investment Excellence List.
September 2025
Rona Therapeutics announced IND filing of RN3161, a highly potent and durable INHBE siRNA for obesity.
*Data updated in 2025
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...
